Breakthrough trial LT3001 shows functional improvement in patients with acute ischemic stroke, ineligible for standard therapies. Presented at conference.
Results from a Phase 2 trial reveal promising findings for patients who cannot undergo standard reperfusion therapies. This data was presented at the International Stroke Conference and highlights the efficacy of LT3001 in providing significant functional improvements for patients with disabling Acute Ischemic Stroke (AIS). The trial showcased that LT3001 delivers meaningful outcomes for patients ineligible for standard treatments.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments